Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout Zacks.com 1/18/2021
In an effort to expand its cell and gene vaccines and therapies footprint internationally,
Thermo Fisher Scientific Inc. TMO recently acquired Belgium-based Henogen S.A. Henogen is the viral vector manufacturing business of life sciences service and technology supplier, Groupe Novasep SAS.
Popular Searches
Per the financial terms of the deal, Thermo Fisher completed this acquisition for a deal value of approximately €725 million (roughly $880 million) in cash. This business will get integrated within Thermo Fisher’s Pharma Services business within the broader Laboratory Products and Services Segment.
A Glimpse of Henogen’s Business